Literature DB >> 15918159

Guidelines for good pharmacoepidemiology practices (GPP).

Mark Epstein1.   

Abstract

Mesh：

Year:  2005        PMID： 15918159     DOI： 10.1002/pds.1082

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  18 in total

1.  Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan.

Authors:  Choitsu Sakamoto; Kentaro Sugano; Shinichi Ota; Nobuhiro Sakaki; Shin'ichi Takahashi; Yukio Yoshida; Taku Tsukui; Hiroyuki Osawa; Yukihiro Sakurai; Junji Yoshino; Yuji Mizokami; Tetsuya Mine; Tetsuo Arakawa; Hajime Kuwayama; Katsunori Saigenji; Koji Yakabi; Tsutomu Chiba; Tooru Shimosegawa; Jane E Sheehan; Susana Perez-Gutthann; Takuhiro Yamaguchi; David W Kaufman; Tsugumichi Sato; Kiyoshi Kubota; Akira Terano
Journal:  Eur J Clin Pharmacol       Date:  2006-07-04       Impact factor: 2.953

Review 2.  Toward a better understanding about real-world evidence.

Authors:  Mei Liu; Yana Qi; Wen Wang; Xin Sun
Journal:  Eur J Hosp Pharm       Date:  2021-12-02

3.  Treatment Patterns among Patients with Atopic Dermatitis in Secondary Care: A National, Observational, Non-interventional, Retrospective Study in Sweden.

Authors:  Emma K Johansson; Andreas Brenneche; Dennis Trangbaek; M Natalia Stelmaszuk; Jonatan Freilich; Chris D Anderson
Journal:  Acta Derm Venereol       Date:  2022-09-06       Impact factor: 3.875

Review 4.  Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.

Authors:  Deborah Layton; Saad A W Shakir
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

5.  Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.

Authors:  Jürgen Behr; Michael Kreuter; Marius M Hoeper; Hubert Wirtz; Jens Klotsche; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Winfried Randerath; Dirk Skowasch; F Joachim Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Rudolf Maria Huber; Claus Neurohr; Martin Schwaiblmair; Martin Kohlhäufl; Gert Höffken; Matthias Held; Andrea Koch; Thomas Bahmer; David Pittrow
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

6.  Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership.

Authors:  Nancy A Dreyer; Stella Blackburn; Valerie Hliva; Shahrul Mt-Isa; Jonathan Richardson; Anna Jamry-Dziurla; Alison Bourke; Rebecca Johnson
Journal:  JMIR Med Inform       Date:  2015-04-15

7.  Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.

Authors:  Juergen Behr; Marius M Hoeper; Michael Kreuter; Jens Klotsche; Hubert Wirtz; David Pittrow
Journal:  BMJ Open Respir Res       Date:  2014-01-03

8.  Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Authors:  Graham R Foster; Carmine Coppola; Moutaz Derbala; Peter Ferenci; Alessandra Orlandini; K Rajender Reddy; Ludovico Tallarico; Mitchell L Shiffman; Silke Ahlers; Georgios Bakalos; Tarek Hassanein
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

9.  Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.

Authors:  Valéry Risson; Deepanshu Saini; Ian Bonzani; Alice Huisman; Melvin Olson
Journal:  J Med Internet Res       Date:  2016-03-17       Impact factor: 5.428

10.  Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan.

Authors:  Tzu-Hsien Lai; Wen-Fu Wang; Bak-Sau Yip; Yu-Wan Yang; Giia-Sheun Peng; Shih-Jei Tsai; Yi-Chu Liao; Ming-Chyi Pai
Journal:  Patient Prefer Adherence       Date:  2016-03-30       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.